# Patients With Brain Metastases From HER2-positive Breast Cancer

> **NCT02135159** · PHASE1 · COMPLETED · sponsor: **Institut du Cancer de Montpellier - Val d'Aurelle** · enrollment: 36 (actual)

## Conditions studied

- HER2-positive Breast Cancer

## Interventions

- **DRUG:** TDM1
- **RADIATION:** Brain Sequential RT

## Key facts

- **NCT ID:** NCT02135159
- **Lead sponsor:** Institut du Cancer de Montpellier - Val d'Aurelle
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02
- **Primary completion:** 2017-02
- **Final completion:** 2017-03
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2017-08-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02135159

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02135159, "Patients With Brain Metastases From HER2-positive Breast Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02135159. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*